Skip to main content
HYFT
NASDAQ Life Sciences

MindWalk Launches ReefIQ™ AI Platform for Enhanced Drug Discovery

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.8
Mkt Cap
$84.081M
52W Low
$0.51
52W High
$3.246
52W Position info
253% above low
Off High info
45% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

HYFT has more than doubled off its 52-week low of $0.51.

Summary

MindWalk Holdings Corp. launched ReefIQ™, a new biological context layer powered by its HYFT® AI system, designed to enhance AI drug discovery by organizing fragmented biological data into a queryable, governed knowledge base.


Key Events · Product Development and Regulatory · HYFT

  • ReefIQ™ Platform Launch

    MindWalk Holdings Corp. introduced ReefIQ™, a new biological context layer for AI drug discovery and biologics development. This platform leverages the company's proprietary HYFT® technology to transform fragmented biological data into a governed, queryable context for AI reasoning workflows.

  • Enhances AI Drug Discovery

    ReefIQ™ is designed to bridge the gap where insights are lost due to disconnected data, preserving program learnings and providing a trustworthy foundation for AI models like LensAI™ to generate hypotheses and support decision-making in a regulated setting.

  • Strategic Product Expansion

    This launch operationalizes the HYFT information network, linking customer data to MindWalk's biological representation foundation and is intended to be foundational for future life-sciences engagements, building on existing contracted arrangements for LensAI™.


Analysis · HYFT · Life Sciences

This launch is a significant step in MindWalk's strategy to build robust BioIntelligence infrastructure. By providing a structured, queryable biological context, ReefIQ™ addresses a critical challenge in AI drug discovery: data fragmentation. This enhancement to their core HYFT® and LensAI™ platforms strengthens their competitive advantage and could accelerate drug development for their partners, potentially leading to increased adoption and revenue.

How filings like this one have moved

In the 30 days to Sep 18, 2026, 35.4% of the 1144 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.40%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HYFT was trading at $1.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.1M. The 52-week trading range was $0.51 to $3.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HYFT - Latest Insights

HYFT
Sep 14, 2026, 4:58 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.30
Real-time Price: $1.37 info
Change: +$0.070 (+5%) info
Market Cap: $64.543M info
HYFT
Sep 14, 2026, 4:57 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $1.30
Real-time Price: $1.37 info
Change: +$0.070 (+5%) info
Market Cap: $64.543M info
HYFT
Sep 14, 2026, 4:56 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $1.35
Real-time Price: $1.37 info
Change: +$0.0202 (+1%) info
Market Cap: $64.543M info
HYFT
Sep 14, 2026, 8:46 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $1.37
Real-time Price: $1.37 info
Change: $0 (0%) info
Market Cap: $64.543M info
HYFT
Jul 22, 2026, 6:36 PM EDT
Filing Type: 20-F
Importance Score:
9
Price at Filing: $1.28
Real-time Price: $1.37 info
Change: +$0.090 (+7%) info
Market Cap: $64.543M info